Brad Thompson
Calgary, AB T2T2P9, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Efficient and safe lung gene delivery using AAV6.2FF in neonatal pigs demonstrates pediatric translational potential.
Journal: Molecular therapy. Advances
Published: September 09, 2025
AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia.
Journal: Gene therapy
Published: November 01, 2023
AAV-Vectored Expression of Marburg Virus-Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model.
Journal: The Journal of infectious diseases
Published: August 28, 2023
Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate Model.
Journal: Biomedicines
Published: July 09, 2023
Antibody-based protection against respiratory syncytial virus in mice and their offspring through vectored immunoprophylaxis.
Journal: Gene therapy
Published: September 18, 2022
Adeno-associated virus mediated expression of monoclonal antibody MR191 protects mice against Marburg virus and provides long-term expression in sheep.
Journal: Gene therapy
Published: April 14, 2022
AAV-monoclonal antibody expression protects mice from Ebola virus without impeding the endogenous antibody response to heterologous challenge.
Journal: Molecular therapy. Methods & clinical development
Published: January 26, 2022
AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma.
Journal: Biomedicines
Published: December 05, 2021
Safety and Tolerability of the Adeno-Associated Virus Vector, AAV6.2FF, Expressing a Monoclonal Antibody in Murine and Ovine Animal Models.
Journal: Biomedicines
Published: August 16, 2021
AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge.
Journal: Gene therapy
Published: November 11, 2020
A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma.
Journal: Cancer chemotherapy and pharmacology
Published: November 18, 2016
Last Updated: 09/26/2026